Edition:
United Kingdom

People: CASI Pharmaceuticals Inc (CASI.OQ)

CASI.OQ on NASDAQ Stock Exchange Capital Market

3.30USD
23 Apr 2019
Change (% chg)

$-0.01 (-0.30%)
Prev Close
$3.31
Open
$3.34
Day's High
$3.34
Day's Low
$3.28
Volume
4,005
Avg. Vol
77,028
52-wk High
$8.88
52-wk Low
$2.74

Ren, Ken 

Dr. Ken Keyong Ren, Ph.D., is Director of the Company. he was Chief Executive Officer of the company. Dr. Ren joined the Company in April 2012 as interim Chief Executive Officer, and after successful completion of the one-year interim period, was appointed Chief Executive Officer in April 2013, and in December 2014 was elected to the Board of Directors. Prior to joining the Company, from 2005-2012, Dr. Ren was the president of Accelovance (China), a subsidiary of Accelovance, Inc., which is a Maryland-based contract research organization. Prior to Accelovance, Dr. Ren was the founder of New Jersey-based AHT Inc., which merged with Novemed, a portfolio investment of a blue-chip public company in Hong Kong. He was a co-founder of the China Innovation Center for Life Science (U.S.A.) Corp., a New York-based consulting firm in partnership with the Chinese Ministry of Science and Technology which provided consulting services to health-care and pharmaceutical companies in both the U.S. and China. Over the past 15 years Dr. Ren has been involved in several U.S./China based start-up companies in pharmaceutical development or services. Dr. Ren was a research scientist at Pfizer from 1993–1995 and a Research Fellow at Rockefeller University from 1990–1993. He received his medical degree at the Shandong University School of Medicine in China in 1986 and a Ph.D. from State University of New York at Buffalo in 1990. Dr. Ren’s qualifications to serve on the Board of Directors include his extensive leadership experience and background in the healthcare and pharmaceutical industries, which make him well qualified to serve on our Board of Directors.

Basic Compensation

Total Annual Compensation, USD 759,375
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 29,040
Fiscal Year Total, USD 788,415

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Wei-Wu He

121,000

George Chi

--

Cynthia Hu

467,099

Sara Capitelli

292,803

Rong Chen

--

Tak Mak

--
As Of  31 Dec 2017